FTC agrees to re-open Actavis and Watson merger decision
19-12-2018
parbradyphoto / iStockphoto.com
The US Federal Trade Commission (FTC) yesterday said that Teva Pharmaceuticals has asked the commission to reopen and modify its decision and order regarding the 2012 merger of Actavis and Watson Pharmaceuticals.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
supply agreement, generic, generic drugs, big pharma, US Federal Trade Commission, FTC, Teva Pharmaceuticals, Pfizer, Allergan, Actavis
